{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:43:50Z","timestamp":1794663830973,"version":"4.9.1"},"reference-count":336,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.eururo.2024.09.017","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:52:57Z","timestamp":1728607977000},"page":"157-216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":145,"title":["Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)"],"prefix":"10.1016","volume":"87","author":[{"given":"Silke","family":"Gillessen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-7888","authenticated-orcid":false,"given":"Fabio","family":"Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo Assed","family":"Bastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol","family":"Axcrona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"Ayadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himisha","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Bjartell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Bourlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Bulbul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Buttigliero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orazio","family":"Caffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline S.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onyeanunam N.","family":"Ekeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer I.H.","family":"El Nahas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omolara A.","family":"Fatiregun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix Y.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.C.","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Fonteyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.","family":"Gleave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenaelle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G.","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha H.A.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindren","family":"Kanesvaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Keizman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja B.","family":"Khauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gero","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Loeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon A.","family":"Mahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Maluf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Mateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Matheson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika P.","family":"Matikainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel S.","family":"Merseburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Mrabti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Mukherji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingai B.A.","family":"Mutambirwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William K.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe M.","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar R.","family":"Padhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren M.C.","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin C.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny M","family":"Rabah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Rathkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphaele","family":"Renard-Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Sade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver A.","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard I.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona A.","family":"Skoneczna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard R.","family":"Soule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora N.","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Ellen","family":"Taplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Thellenberg-Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent N.","family":"T\u00fcrkeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y\u00fcksel","family":"\u00dcr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire L.","family":"Vale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Vapiwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosj","family":"Yamoah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena","family":"Zapatero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelius","family":"Omlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.09.017_b0005","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","article-title":"Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015","volume":"26","author":"Gillessen","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0010","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","article-title":"Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019","volume":"77","author":"Gillessen","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0015","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","article-title":"Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017","volume":"73","author":"Gillessen","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2022.11.002","article-title":"Management of patients with advanced prostate cancer. Part I: intermediate-\/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the Advanced Prostate Cancer Consensus Conference 2022","volume":"83","author":"Gillessen","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0025","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2024.09.017_b0030","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0035","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"Prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.eururo.2024.09.017_b0040","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.euo.2023.12.005","article-title":"Comparing the performance of digital rectal examination and prostate-specific antigen as a screening test for prostate cancer: a systematic review and meta-analysis","volume":"7","author":"Matsukawa","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0045","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/jmri.27485","article-title":"Whole-body magnetic resonance imaging for prostate cancer assessment: current status and future directions","volume":"55","author":"Van Nieuwenhove","year":"2022","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.eururo.2024.09.017_b0050","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.09.017_b0055","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.117.197160","article-title":"The impact of 68Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study","volume":"59","author":"Roach","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.017_b0060","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0065","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0070","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0075","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2967\/jnumed.117.191031","article-title":"PSMA ligands for PET imaging of prostate cancer","volume":"58","author":"Schwarzenboeck","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.017_b0080","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1007\/s00259-021-05424-x","article-title":"Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging","volume":"48","author":"Gr\u00fcnig","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.017_b0085","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00259-021-05520-y","article-title":"Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 PET\/CT imaging in patients with confirmed prostate cancer","volume":"49","author":"Pattison","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.017_b0090","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the Prostate Cancer Molecular Imaging Standardized Evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0095","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.017_b0100","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1148\/rg.2018170108","article-title":"Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls","volume":"38","author":"Hofman","year":"2018","journal-title":"Radiographics"},{"key":"10.1016\/j.eururo.2024.09.017_b0105","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.09.017_b0110","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0115","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.eururo.2023.04.024","article-title":"Androgen deprivation and radiotherapy with or without docetaxel for localized high-risk prostate cancer: long-term follow-up from the randomized NRG Oncology RTOG 0521 trial","volume":"84","author":"Sartor","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0120","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkac043","article-title":"Docetaxel for nonmetastatic prostate cancer: long-term survival outcomes in the STAMPEDE randomized controlled trial","volume":"6","author":"James","year":"2022","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.eururo.2024.09.017_b0125","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0130","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.20.02438","article-title":"Prostate radiotherapy with adjuvant androgen deprivation therapy (ADT) improves metastasis-free survival compared to neoadjuvant ADT: an individual patient meta-analysis","volume":"39","author":"Spratt","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0135","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.19.01904","article-title":"Sequencing of androgen-deprivation therapy with external-beam radiotherapy in localized prostate cancer: a phase III randomized controlled trial","volume":"38","author":"Malone","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0140","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.22.00970","article-title":"Sequencing of androgen-deprivation therapy of short duration with radiotherapy for nonmetastatic prostate cancer (SANDSTORM): a pooled analysis of 12 randomized trials","volume":"41","author":"Ma","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0145","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006019","article-title":"Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer","volume":"2006","author":"Kumar","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2024.09.017_b0150","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2007.07.035","article-title":"The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study","volume":"53","author":"Mattei","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0155","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eururo.2016.12.003","article-title":"The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review","volume":"72","author":"Fossati","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0160","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1097\/01.ju.0000091805.98960.13","article-title":"A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer","volume":"170","author":"Cagiannos","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0165","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2011.10.044","article-title":"Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores","volume":"61","author":"Briganti","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0170","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2018.10.012","article-title":"A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies","volume":"75","author":"Gandaglia","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0175","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.eururo.2020.03.023","article-title":"External validation of the 2019 Briganti nomogram for the identification of prostate cancer patients who should be considered for an extended pelvic lymph node dissection","volume":"78","author":"Gandaglia","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0180","doi-asserted-by":"crossref","first-page":"17985","DOI":"10.1038\/s41598-019-54261-4","article-title":"Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database","volume":"9","author":"Chen","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2024.09.017_b0185","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/JU.0000000000000504","article-title":"Effect of extended pelvic lymph node dissection on oncologic outcomes in patients with D\u2019Amico intermediate and high risk prostate cancer treated with radical prostatectomy: a multi-institutional study","volume":"203","author":"Preisser","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0190","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.eururo.2006.08.015","article-title":"Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer","volume":"50","author":"Briganti","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0195","series-title":"Presented at the 2024 European Association of Urology annual congress, Paris, France, April 5\u20138","article-title":"Pelvic lymph node dissection in prostate cancer: update of the limited vs. extended randomized clinical trial","author":"Touijer","year":"2024"},{"key":"10.1016\/j.eururo.2024.09.017_b0200","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.euo.2021.03.006","article-title":"Limited versus extended pelvic lymph node dissection for prostate cancer: a randomized clinical trial","volume":"4","author":"Touijer","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0205","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eururo.2019.10.008","article-title":"Local failure and survival after definitive radiotherapy for aggressive prostate cancer: an individual patient-level meta-analysis of six randomized trials","volume":"77","author":"Kishan","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0210","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2022.04.003","article-title":"High-dose radiotherapy or androgen deprivation therapy (HEAT) as treatment intensification for localized prostate cancer: an individual patient-data network meta-analysis from the MARCAP Consortium","volume":"82","author":"Kishan","year":"2022","journal-title":"Eur Urol"},{"issue":"4 Suppl","key":"10.1016\/j.eururo.2024.09.017_b0215","article-title":"Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial","volume":"42","author":"Hennequin","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0220","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2014.08.009","article-title":"A systematic review of hypofractionation for primary management of prostate cancer","volume":"68","author":"Koontz","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0225","article-title":"Hypofractionation for clinically localized prostate cancer","volume":"2019","author":"Hickey","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.09.017_b0230","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2023.41.6_suppl.304","article-title":"10-Year efficacy and co-morbidity outcomes of a phase III randomised trial of conventional vs. hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP; CRUK\/06\/016)","volume":"41","author":"Syndikus","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0235","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0240","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.euo.2022.10.001","article-title":"Magnetic resonance imaging\u2013guided focal boost to intraprostatic lesions using external beam radiotherapy for localized prostate cancer: a systematic review and meta-analysis","volume":"6","author":"Poon","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0245","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3390\/cancers13040759","article-title":"Stereotactic body radiotherapy for high-risk prostate cancer: a systematic review","volume":"13","author":"Foerster","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2024.09.017_b0250","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.09.017_b0255","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ijrobp.2021.01.016","article-title":"Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: analysis of 344 prospectively treated patients","volume":"110","author":"van Dams","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2024.09.017_b0260","first-page":"S2652","article-title":"Acute toxicity from PACE-C comparing stereotactic body radiotherapy (SBRT) with moderate hypofractionation (MHRT)","volume":"194","author":"Tree","year":"2024","journal-title":"Radiother Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2024.09.017_b0265","doi-asserted-by":"crossref","first-page":"S770","DOI":"10.1016\/S0167-8140(23)08750-9","article-title":"Prostate RT In high risk or N+ Moderate vs Extreme hypofractionation (PRIME): an interim analysis","volume":"182","author":"Murthy","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0270","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ijrobp.2016.06.2455","article-title":"Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study","volume":"96","author":"Pommier","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.09.017_b0275","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.radonc.2019.12.006","article-title":"Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): a randomised trial","volume":"145","author":"Murthy","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0280","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0285","doi-asserted-by":"crossref","unstructured":"Maitre P, Maheshwari G, Sarkar J, et al. Late urinary toxicity and quality of life with pelvic radiation therapy for high-risk prostate cancer: dose-effect relations in the POP-RT randomized phase 3 trial. Int J Radiat Oncol Biol Phys. In press. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.03.023.","DOI":"10.1016\/j.ijrobp.2024.03.023"},{"key":"10.1016\/j.eururo.2024.09.017_b0290","doi-asserted-by":"crossref","first-page":"830.e17","DOI":"10.1016\/j.urolonc.2021.04.031","article-title":"Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center","volume":"39","author":"W\u00fcrnschimmel","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0295","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.09.017_b0300","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0305","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0310","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.09.017_b0315","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.annonc.2024.03.010","article-title":"Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)","volume":"35","author":"Parker","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0320","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0022-5347(01)61640-9","article-title":"Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison","volume":"161","author":"Ghavamian","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0325","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0330","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.eururo.2013.03.053","article-title":"Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy","volume":"65","author":"Touijer","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0335","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s00345-017-2079-4","article-title":"Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment","volume":"35","author":"Mandel","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0340","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.euo.2020.08.005","article-title":"Management of patients with node-positive prostate cancer at radical prostatectomy and pelvic lymph node dissection: a systematic review","volume":"3","author":"Marra","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0345","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1200\/JCO.2016.70.2811","article-title":"Individual patient-level meta-analysis of the performance of the Decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease","volume":"35","author":"Spratt","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0350","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A systematic review of the evidence for the Decipher genomic classifier in prostate cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0355","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1200\/JCO.2016.69.9918","article-title":"Genomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: development and internal validation of a multivariable prognostic model","volume":"35","author":"Dalela","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0360","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1200\/JCO.2014.59.0026","article-title":"Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy","volume":"33","author":"Den","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0365","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II\u20142024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0370","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.juro.2009.07.022","article-title":"Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database","volume":"182","author":"Moreira","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0375","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/j.1464-410X.2009.09016.x","article-title":"Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database","volume":"105","author":"Moreira","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.09.017_b0380","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.eururo.2017.11.024","article-title":"Performance of a prostate cancer genomic classifier in predicting metastasis in men with prostate-specific antigen persistence postprostatectomy","volume":"74","author":"Spratt","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0385","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2019.01.048","article-title":"Persistent prostate-specific antigen after radical prostatectomy and its impact on oncologic outcomes","volume":"76","author":"Preisser","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0390","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3390\/cancers13050948","article-title":"Prognostic significance of prostate-specific antigen persistence after radical prostatectomy: a systematic review and meta-analysis","volume":"13","author":"Kimura","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2024.09.017_b0395","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.euo.2021.01.001","article-title":"Management of persistently elevated prostate-specific antigen after radical prostatectomy: a systematic review of the literature","volume":"4","author":"Ploussard","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"3 Suppl","key":"10.1016\/j.eururo.2024.09.017_b0400","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.ijrobp.2020.07.2103","article-title":"The impact of persistently elevated PSA after prostatectomy in men with recurrent prostate cancer in NRG Oncology\/RTOG 9601","volume":"108","author":"Birer","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.09.017_b0405","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","article-title":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial","volume":"20","author":"Carrie","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0410","doi-asserted-by":"crossref","unstructured":"Parker CC, Kynaston H, Cook AD, et al. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. Lancet. In press. https:\/\/doi.org\/10.1016\/s0140-6736(24)00549-x.","DOI":"10.1016\/S0140-6736(24)00549-X"},{"key":"10.1016\/j.eururo.2024.09.017_b0415","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/cncr.30620","article-title":"Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: results of NRG Oncology\/RTOG study 0621","volume":"123","author":"Hurwitz","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2024.09.017_b0420","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0425","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0430","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.017_b0435","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and Leukemia Group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0440","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0445","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0450","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.eururo.2017.12.023","article-title":"Intermediate endpoints after postprostatectomy radiotherapy: 5-year distant metastasis to predict overall survival","volume":"74","author":"Jackson","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0455","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1002\/cncr.25013","article-title":"Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death","volume":"116","author":"Choueiri","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2024.09.017_b0460","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.eururo.2019.03.016","article-title":"External validation of the European Association of Urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a European cohort","volume":"75","author":"Tilki","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0465","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/JU.0000000000003892","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0470","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.eururo.2017.07.026","article-title":"Impact of early salvage radiation therapy in patients with persistently elevated or rising prostate-specific antigen after radical prostatectomy","volume":"73","author":"Fossati","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0475","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.017_b0480","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.juro.2016.08.106","article-title":"Very early salvage radiotherapy improves distant metastasis-free survival","volume":"197","author":"Abugharib","year":"2017","journal-title":"J Urol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.09.017_b0485","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.2022.40.6_suppl.262","article-title":"Early initiation of salvage radiotherapy is associated with improved metastasis-free survival in patients with relapsed prostate cancer following prostatectomy","volume":"40","author":"Lee","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2024.09.017_b0490","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1200\/JCO.2023.41.16_suppl.5091","article-title":"PSMA PET findings in an \u201cEMBARK-like\u201d cohort of patients with high-risk non-metastatic hormone-sensitive prostate cancer: a single center post-hoc retrospective analysis","volume":"41","author":"Armstrong","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0495","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.017_b0500","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.09.017_b0505","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/S0140-6736(24)00548-8","article-title":"Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"issue":"Suppl 7","key":"10.1016\/j.eururo.2024.09.017_b0510","doi-asserted-by":"crossref","first-page":"S1428","DOI":"10.1016\/j.annonc.2022.08.067","article-title":"LBA64 Duration of androgen suppression with post-operative radiotherapy (DADSPORT): a collaborative meta-analysis of aggregate data","volume":"33","author":"Burdett","year":"2022","journal-title":"Ann Oncol"},{"issue":"3 Suppl","key":"10.1016\/j.eururo.2024.09.017_b0515","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.ijrobp.2022.07.396","article-title":"The influence of pelvic lymph node dissection volumes on clinical outcomes in NRG\/RTOG 0534","volume":"114","author":"Hall","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.09.017_b0520","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.eururo.2017.10.009","article-title":"Multi-institutional evaluation of elective nodal irradiation and\/or androgen deprivation therapy with postprostatectomy salvage radiotherapy for prostate cancer","volume":"74","author":"Ramey","year":"2018","journal-title":"Eur Urol"},{"issue":"Suppl 3","key":"10.1016\/j.eururo.2024.09.017_b0525","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bju.16158","article-title":"The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy","volume":"133","author":"Roberts","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.09.017_b0530","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.euf.2020.12.010","article-title":"The multicenter, randomized, phase 2 PEACE V-STORM trial: defining the best salvage treatment for oligorecurrent nodal prostate cancer metastases","volume":"7","author":"Zilli","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2024.09.017_b0535","first-page":"2492","article-title":"Salvage treatment of oligorecurrent nodal prostate cancer metastases (STORM)","volume":"194","author":"Ost","year":"2024","journal-title":"Radiother Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.09.017_b0540","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/JCO.2023.41.6_suppl.303","article-title":"FORMULA-509: a multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate\/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP)","volume":"41","author":"Nguyen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0545","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.780507","article-title":"Drug intensification in future postoperative radiotherapy practice in biochemically-relapsing prostate cancer patients","volume":"11","author":"Cailleteau","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0550","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.09.017_b0555","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0560","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0565","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1093\/annonc\/mdx312","article-title":"Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from \u2018castration-resistant\u2019 prostate cancer","volume":"28","author":"Pezaro","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0570","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/annonc\/mdx648","article-title":"Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet","volume":"29","author":"Armstrong","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0575","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00a0\u00d7\u00a02 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.09.017_b0580","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.017_b0585","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMc2205310","article-title":"Darolutamide in metastatic prostate cancer","volume":"386","author":"Turco","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.017_b0590","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2024.09.017_b0595","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0600","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0605","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"Vale","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0610","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2021.05.016","article-title":"Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy","volume":"80","author":"Sweeney","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0615","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.017_b0620","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.017_b0625","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.017_b0630","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.017_b0635","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0640","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.09.017_b0645","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boev\u00e9","year":"2019","journal-title":"Eur Urol"},{"issue":"17 Suppl","key":"10.1016\/j.eururo.2024.09.017_b0650","article-title":"Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): results of PEACE-1, a phase 3 randomized trial with a 2\u00a0\u00d7\u00a02 design","volume":"41","author":"Bossi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0655","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12032-020-01385-7","article-title":"Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer","volume":"37","author":"Reyes","year":"2020","journal-title":"Med Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0660","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.urology.2016.10.044","article-title":"A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer","volume":"102","author":"O\u2019Shaughnessy","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2024.09.017_b0665","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12032-022-01662-7","article-title":"Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer","volume":"39","author":"Reyes","year":"2022","journal-title":"Med Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0670","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190353","article-title":"Prostate cancer with low burden skeletal disease at diagnosis: outcome of concomitant radiotherapy on primary tumor and metastases","volume":"93","author":"Deantoni","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.eururo.2024.09.017_b0675","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0680","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0685","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0690","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.09.017_b0695","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0700","doi-asserted-by":"crossref","unstructured":"Turco F, Tombal B, Gillessen S, Omlin A. Is there a place for de-escalating therapy in patients with metastatic hormone-sensitive prostate cancer? Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/j.euf.2024.06.008.","DOI":"10.1016\/j.euf.2024.06.008"},{"key":"10.1016\/j.eururo.2024.09.017_b0705","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.017_b0710","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1200\/JCO.2012.46.5492","article-title":"Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials","volume":"31","author":"Niraula","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0715","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","volume":"77","author":"Matsubara","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0720","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2024.09.017_b0725","doi-asserted-by":"crossref","first-page":"S776","DOI":"10.1016\/S0302-2838(22)00600-5","article-title":"Clinical outcomes of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with prostate-specific antigen (PSA) decline to undetectable levels on enzalutamide (ENZA): post hoc analysis of ARCHES","volume":"81","author":"Stenzl","year":"2022","journal-title":"Eur Urol"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2024.09.017_b0730","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1200\/JCO.2024.42.16_suppl.5079","article-title":"Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: landmark analysis of ENZAMET (ANZUP 1304)","volume":"42","author":"Laughlin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2024.09.017_b0735","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1200\/JCO.2022.40.16_suppl.5078","article-title":"Association of prostate-specific antigen (PSA) response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial","volume":"40","author":"Saad","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0740","doi-asserted-by":"crossref","first-page":"1391825","DOI":"10.3389\/fonc.2024.1391825","article-title":"EORTC 2238 \u201cDe-Escalate\u201d: a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors","volume":"14","author":"Grisay","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0745","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/ijms25010078","article-title":"Synthetic lethality by co-inhibition of androgen receptor and polyadenosine diphosphate-ribose in metastatic prostate cancer","volume":"25","author":"Calabrese","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eururo.2024.09.017_b0750","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.eururo.2024.09.017_b0755","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1200\/PO.19.00346","article-title":"Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations","volume":"4","author":"Mota","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0760","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2015.11.022","article-title":"Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer","volume":"69","author":"Cheng","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0765","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1002\/cncr.30808","article-title":"The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer","volume":"123","author":"Pomerantz","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2024.09.017_b0770","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2024.09.017_b0775","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","article-title":"Aggressive variants of castration-resistant prostate cancer","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2024.09.017_b0780","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41391-021-00332-5","article-title":"Clinical considerations for the management of androgen indifferent prostate cancer","volume":"24","author":"Berchuck","year":"2021","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.eururo.2024.09.017_b0785","first-page":"26","article-title":"Updates of prostate cancer from the 2022 World Health Organization classification of the urinary and male genital tumors","volume":"3","author":"Guo","year":"2023","journal-title":"J Clin Transl Pathol"},{"key":"10.1016\/j.eururo.2024.09.017_b0790","first-page":"41","article-title":"Prostate pathology: what is new in the 2022 WHO classification of urinary and male genital tumors?","volume":"115","author":"Surintrspanont","year":"2022","journal-title":"Pathologica"},{"key":"10.1016\/j.eururo.2024.09.017_b0795","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S1470-2045(19)30408-5","article-title":"Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1\u20132 trial","volume":"20","author":"Corn","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0800","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0140-6736(22)01482-9","article-title":"The addition of pelvic lymph node treatment to prostate bed salvage radiotherapy","volume":"400","author":"Turco","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.09.017_b0805","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.017_b0810","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0815","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.017_b0820","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.eururo.2024.09.017_b0825","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.2024.42.4_suppl.165","article-title":"Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial","volume":"42","author":"Shore","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0830","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0835","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0840","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.09.017_b0845","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2024.09.017_b0850","doi-asserted-by":"crossref","first-page":"S1326","DOI":"10.1016\/j.annonc.2023.10.087","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.eururo.2024.09.017_b0855","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.2024.42.4_suppl.18","article-title":"CONTACT-02: phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Agarwal","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2024.09.017_b0860","doi-asserted-by":"crossref","first-page":"S1324","DOI":"10.1016\/j.annonc.2023.10.085","article-title":"LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)","volume":"34","author":"Sartor","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0865","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S1470-2045(22)00560-5","article-title":"Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study","volume":"23","author":"Merseburger","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.eururo.2024.09.017_b0870","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1200\/JCO.2024.42.4_suppl.66","article-title":"Underutilization of androgen deprivation therapy (ADT) intensification for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC): a systematic review of real-world database studies","volume":"42","author":"Raval","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0875","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/JU.0000000000003370","article-title":"The role of physician specialty in the underutilization of standard-of-care treatment intensification in patients with metastatic castration-sensitive prostate cancer","volume":"209","author":"Swami","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0880","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1200\/JCO.23.02105","article-title":"Efficacy of poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: a US Food and Drug Administration pooled analysis","volume":"42","author":"Fallah","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0885","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1158\/2159-8290.CD-21-0007","article-title":"Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial","volume":"11","author":"Carreira","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2024.09.017_b0890","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2024.09.017_b0895","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.eururo.2019.09.036","article-title":"Clinical outcomes in cyclin-dependent kinase 12 mutant advanced prostate cancer","volume":"77","author":"Reimers","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0900","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1200\/PO.19.00399","article-title":"CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-ribose) polymerase inhibitors, and PD-1 inhibitors","volume":"4","author":"Antonarakis","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0905","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMcibr1808772","article-title":"Cyclin-dependent kinase 12, immunity, and prostate cancer","volume":"379","author":"Antonarakis","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.017_b0910","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1200\/PO.19.00383","article-title":"CDK12-mutated prostate cancer: clinical outcomes with standard therapies and immune checkpoint blockade","volume":"4","author":"Schweizer","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.eururo.2024.09.017_b0915","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2024.42.4_suppl.19","article-title":"BRCAAway: a randomized phase 2 trial of abiraterone, olaparib, or abirateroneolaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm)","volume":"42","author":"Hussain","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0920","doi-asserted-by":"crossref","first-page":"e2100531","DOI":"10.1200\/PO.21.00531","article-title":"PARP inhibitor insensitivity to BRCA1\/2 monoallelic mutations in microsatellite instability-high cancers","volume":"6","author":"Sokol","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0925","doi-asserted-by":"crossref","DOI":"10.1177\/17562872241229876","article-title":"Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial","volume":"16","author":"Coquan","year":"2024","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0930","doi-asserted-by":"crossref","DOI":"10.2196\/54086","article-title":"Carboplatin in patients with metastatic castration-resistant prostate cancer harboring somatic or germline homologous recombination repair gene mutations: phase II single-arm trial","volume":"13","author":"Jain","year":"2024","journal-title":"JMIR Res Protoc"},{"key":"10.1016\/j.eururo.2024.09.017_b0935","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.21692","article-title":"Activity of platinum-based chemotherapy in patients with advanced prostate cancer with and without DNA repair gene aberrations","volume":"3","author":"Schmid","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2024.09.017_b0940","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0945","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.017_b0950","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.2018.77.9827","article-title":"Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment","volume":"36","author":"Attard","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0955","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.eururo.2017.07.035","article-title":"Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for \u226524 weeks in Europe","volume":"74","author":"de Bono","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0960","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.862995","article-title":"Oligoprogression in metastatic, castrate-resistant prostate cancer-prevalence and current clinical practice","volume":"12","author":"Patel","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0965","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/pros.24132","article-title":"Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone\/enzalutamide treatment","volume":"81","author":"Onal","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2024.09.017_b0970","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/j.ijrobp.2021.07.869","article-title":"Metastasis-directed therapy for oligoprogressive castration-resistant prostate cancer\u2014preliminary results of the prospective, single-arm MEDCARE trial","volume":"111","author":"Berghen","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.09.017_b0975","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1007\/s00345-019-02717-7","article-title":"Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study","volume":"37","author":"Triggiani","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b0980","doi-asserted-by":"crossref","unstructured":"Rans K, Joniau S, Berghen C, et al. Progression-directed therapy in oligoprogressive castration-resistant prostate cancer: final results from the prospective, single-arm, phase 2 MEDCARE trial. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2024.04.003.","DOI":"10.1016\/j.euo.2024.04.003"},{"key":"10.1016\/j.eururo.2024.09.017_b0985","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1200\/JCO.23.00985","article-title":"Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO)","volume":"41","author":"Francolini","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0990","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1200\/JCO.23.00753","article-title":"Prophylactic radiation therapy versus standard of care for patients with high-risk asymptomatic bone metastases: a multicenter, randomized phase II clinical trial","volume":"42","author":"Gillespie","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b0995","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(22)00092-4","article-title":"Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial","volume":"23","author":"Dearnaley","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1000","first-page":"339","article-title":"Treatment landscape for patients with castration-resistant prostate cancer: patient selection and unmet clinical needs","volume":"14","author":"Turco","year":"2022","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b1005","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/cac2.12340","article-title":"Treatment intensification for metastatic prostate cancer: new treatment landscapes in androgen deprivation-based therapy","volume":"42","author":"Turco","year":"2022","journal-title":"Cancer Commun"},{"issue":"15 Suppl","key":"10.1016\/j.eururo.2024.09.017_b1010","article-title":"Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH)","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1015","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.09.017_b1020","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1025","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.017_b1030","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1035","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1040","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00259-023-06536-2","article-title":"Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT\/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study","volume":"51","author":"Neubauer","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.017_b1045","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.2967\/jnumed.122.264770","article-title":"Dual-time-point posttherapy 177Lu-PSMA-617 SPECT\/CT describes the uptake kinetics of mCRPC lesions and prognosticates patients\u2019 outcome","volume":"64","author":"Straub","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.017_b1050","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231156392","article-title":"Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)","volume":"15","author":"Emmett","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1055","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41391-020-0222-6","article-title":"Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"23","author":"Mori","year":"2020","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.eururo.2024.09.017_b1060","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00259-019-04674-0","article-title":"New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide","volume":"47","author":"Rosar","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.017_b1065","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3390\/cancers14071696","article-title":"Upregulation of PSMA expression by enzalutamide in patients with advanced mCRPC","volume":"14","author":"Rosar","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2024.09.017_b1070","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(24)00179-7","article-title":"Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer","volume":"25","author":"Hou\u00e9d\u00e9","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1075","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.3390\/ijms22147431","article-title":"Enzalutamide enhances PSMA expression of PSMA-low prostate cancer","volume":"22","author":"Staniszewska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eururo.2024.09.017_b1080","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1085","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","article-title":"A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer","volume":"80","author":"Sadaghiani","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b1090","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2967\/jnumed.123.266391","article-title":"Differences and common ground in 177Lu-PSMA radioligand therapy practice patterns: international survey of 95 theranostic centers","volume":"65","author":"Farolfi","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.017_b1095","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2967\/jnumed.119.236414","article-title":"Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer","volume":"61","author":"Violet","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.017_b1100","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2967\/jnumed.118.215715","article-title":"Early Experience of rechallenge 177Lu-PSMA radioligand therapy after an initial good response in patients with advanced prostate cancer","volume":"60","author":"Gafita","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.017_b1105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s13139-021-00696-5","article-title":"The outcome and safety of re-challenge lutetium-177 PSMA (177Lu-PSMA) therapy with low-dose docetaxel as a radiosensitizer\u2014a promising combination in metastatic castrate-resistant prostate cancer (mCRPC): a case report","volume":"55","author":"Maharaj","year":"2021","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.017_b1110","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13550-021-00805-7","article-title":"Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"11","author":"Groener","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.eururo.2024.09.017_b1115","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2020.05.004","article-title":"Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement: a multicenter retrospective study","volume":"78","author":"Gafita","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b1120","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/pros.24250","article-title":"Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapy","volume":"82","author":"Widjaja","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2024.09.017_b1125","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2967\/jnumed.123.265986","article-title":"Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy","volume":"65","author":"Steinhelfer","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.017_b1130","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.3390\/cancers13123095","article-title":"Renal safety of [177Lu]Lu-PSMA-617 radioligand therapy in patients with compromised baseline kidney function","volume":"13","author":"Rosar","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.eururo.2024.09.017_b1135","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/bju.15384","article-title":"UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-na\u00efve prostate cancer (clinical trial protocol)","volume":"128","author":"Dhiantravan","year":"2021","journal-title":"BJU Int"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2024.09.017_b1140","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1200\/JCO.2024.42.16_suppl.5003","article-title":"Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-na\u00efve patients with metastatic castration-resistant prostate cancer (PSMAfore)","volume":"42","author":"Fizazi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1145","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.09.017_b1150","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.semnuclmed.2021.11.003","article-title":"Radiation dosimetry in 177Lu-PSMA-617 therapy","volume":"52","author":"Jackson","year":"2022","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.eururo.2024.09.017_b1155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0276063","article-title":"Experiences of participants in a clinical trial of a novel radioactive treatment for advanced prostate cancer: a nested, qualitative longitudinal study","volume":"17","author":"Viljoen","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2024.09.017_b1160","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1059122","article-title":"AlphaBet: Combination of radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)","volume":"9","author":"Kostos","year":"2022","journal-title":"Front Med"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.09.017_b1165","article-title":"LuCAB: a phase I\/II trial evaluating cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Kostos","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1170","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/bju.14814","article-title":"Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team","volume":"124","author":"Murphy","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.09.017_b1175","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.19568","article-title":"Causes of death among patients with metastatic prostate cancer in the US from 2000 to 2016","volume":"4","author":"Elmehrath","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2024.09.017_b1180","doi-asserted-by":"crossref","DOI":"10.1161\/HCG.0000000000000082","article-title":"Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association","volume":"14","author":"Okwuosa","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.eururo.2024.09.017_b1185","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1161\/ATVBAHA.119.313046","article-title":"Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses","volume":"40","author":"Hu","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.eururo.2024.09.017_b1190","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eururo.2024.09.017_b1195","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jaccao.2023.07.005","article-title":"Cardiovascular toxicity during advanced prostate cancer treatment: minding the heart","volume":"5","author":"Dorff","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1200","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaccao.2021.12.001","article-title":"What cardio-oncology lessons can we learn from population-based data?","volume":"4","author":"Klimis","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1205","series-title":"FDA drug safety communication: ongoing safety review of GnRH agonists and possible increased risk of diabetes and certain cardiovascular diseases","author":"US Food and Drug Administration","year":"2010"},{"key":"10.1016\/j.eururo.2024.09.017_b1210","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2024.09.017_b1215","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","article-title":"Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer","volume":"33","author":"O\u2019Farrell","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1220","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bju.12905","article-title":"Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer","volume":"116","author":"Ziehr","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.09.017_b1225","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","article-title":"Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality","volume":"99","author":"Tsai","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2024.09.017_b1230","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2024.09.017_b1235","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","article-title":"Impact of androgen deprivation therapy on cardiovascular disease and diabetes","volume":"27","author":"Alibhai","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1240","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2007.12.3752","article-title":"Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85\u201331","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1245","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology","volume":"121","author":"Levine","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.eururo.2024.09.017_b1250","first-page":"E307","article-title":"Canadian Urological Association guideline on androgen deprivation therapy: adverse events and management strategies","volume":"15","author":"Kokorovic","year":"2021","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eururo.2024.09.017_b1255","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/js.2018-00039","article-title":"Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer","volume":"2","author":"Gagliano-Juc\u00e1","year":"2018","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.eururo.2024.09.017_b1260","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.urolonc.2020.08.003","article-title":"Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer","volume":"39","author":"Morgans","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1265","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/JU.0000000000000384","article-title":"Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease","volume":"202","author":"Margel","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b1270","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.017_b1275","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.eururo.2024.09.017_b1280","doi-asserted-by":"crossref","unstructured":"Lee YHA, Hui JMH, Leung CH, et al. Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study. Prostate Cancer Prostat Dis. In press. https:\/\/doi.org\/10.1038\/s41391-023-00757-0.","DOI":"10.1038\/s41391-023-00757-0"},{"key":"10.1016\/j.eururo.2024.09.017_b1285","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","article-title":"The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2024.09.017_b1290","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/jnci\/djac081","article-title":"Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer","volume":"114","author":"Lai","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2024.09.017_b1295","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jamaoncol.2024.1549","article-title":"Cardiovascular events and androgen receptor signaling inhibitors in advanced prostate cancer: a systematic review and meta-analysis","volume":"10","author":"El-Taji","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1300","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/DDDT.S15850","article-title":"Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer","volume":"6","author":"Rehman","year":"2012","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.eururo.2024.09.017_b1305","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S0022-5347(17)32530-2","article-title":"Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma","volume":"152","author":"Karling","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b1310","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1442-2042.2004.00896.x","article-title":"Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy","volume":"11","author":"Nishiyama","year":"2004","journal-title":"Int J Urol"},{"issue":"Suppl 12B","key":"10.1016\/j.eururo.2024.09.017_b1315","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.amjmed.2005.09.046","article-title":"Hot flashes: behavioral treatments, mechanisms, and relation to sleep","volume":"118","author":"Freedman","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.eururo.2024.09.017_b1320","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/pon.1427","article-title":"Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer","volume":"18","author":"Ulloa","year":"2009","journal-title":"Psychooncology"},{"key":"10.1016\/j.eururo.2024.09.017_b1325","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/13697137.2015.1125460","article-title":"Vasomotor symptoms in prostate cancer survivors undergoing androgen deprivation therapy","volume":"19","author":"Hunter","year":"2016","journal-title":"Climacteric"},{"key":"10.1016\/j.eururo.2024.09.017_b1330","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/13543784.2021.1893305","article-title":"Fezolinetant in the treatment of vasomotor symptoms associated with menopause","volume":"30","author":"Depypere","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.eururo.2024.09.017_b1335","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.juro.2015.03.026","article-title":"Course and moderators of hot flash interference during androgen deprivation therapy for prostate cancer: a matched comparison","volume":"194","author":"Gonzalez","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b1340","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.eururo.2009.02.016","article-title":"Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group","volume":"55","author":"Calais da Silva","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b1345","first-page":"9","article-title":"How to improve the quality of life of patients with prostate cancer treated with hormone therapy?","volume":"15","author":"Turco","year":"2023","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b1350","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1464-410X.1989.tb05288.x","article-title":"Hot flushes are induced by thermogenic stimuli","volume":"64","author":"McCallum","year":"1989","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b1355","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/GME.0000000000001138","article-title":"The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women\u2019s Sexual Health (ISSWSH) expert consensus panel review","volume":"25","author":"Simon","year":"2018","journal-title":"Menopause"},{"issue":"17 Suppl 1","key":"10.1016\/j.eururo.2024.09.017_b1360","article-title":"MANCAN2: a multicentre randomised controlled trial of self-help cognitive behavioural therapy (CBT) to manage hot flush and night sweats (HFNS) symptoms in patients with prostate cancer receiving androgen deprivation therapy (ADT)","volume":"42","author":"Crabb","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1365","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ijrobp.2010.01.025","article-title":"Acupuncture for the alleviation of hot flashes in men treated with androgen ablation therapy","volume":"79","author":"Ashamalla","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.09.017_b1370","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(09)70338-9","article-title":"Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial","volume":"11","author":"Irani","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1375","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0090-4295(98)00354-9","article-title":"Antiandrogen withdrawal syndrome with cyproterone acetate","volume":"52","author":"Sella","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2024.09.017_b1380","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(21)00100-8","article-title":"Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme","volume":"397","author":"Langley","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.09.017_b1385","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.clon.2023.10.054","article-title":"A repurposing programme evaluating transdermal oestradiol patches for the treatment of prostate cancer within the PATCH and STAMPEDE trials: current results and adapting trial design","volume":"36","author":"Gilbert","year":"2024","journal-title":"Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1390","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s41391-021-00337-0","article-title":"PSA response to antiandrogen withdrawal: a systematic review and meta-analysis","volume":"24","author":"Soo","year":"2021","journal-title":"Prostate Cancer Prostat Dis"},{"issue":"17 Suppl","key":"10.1016\/j.eururo.2024.09.017_b1395","article-title":"Alliance A222001: a randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy","volume":"42","author":"Stish","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1400","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","article-title":"Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study","volume":"401","author":"Lederman","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.09.017_b1405","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jamaoncol.2023.0998","article-title":"association of second-generation antiandrogens with cognitive and functional toxic effects in randomized clinical trials: a systematic review and meta-analysis","volume":"9","author":"Nowakowska","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1410","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.25826","article-title":"Evaluation of fall and fracture risk among men with prostate cancer treated with androgen receptor inhibitors: a systematic review and meta-analysis","volume":"3","author":"Myint","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2024.09.017_b1415","article-title":"Maximal androgen blockade therapy (MAB) for prostate cancer (PC) and risk of bone fractures: a systematic literature review and meta-analysis","volume":"42","author":"Turco","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1420","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41391-023-00775-y","article-title":"Safety profile of darolutamide versus placebo: a systematic review and meta-analysis","volume":"27","author":"Turco","year":"2024","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.eururo.2024.09.017_b1425","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/JU.0000000000001767","article-title":"Indirect comparison of darolutamide versus apalutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer","volume":"206","author":"Halabi","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b1430","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.09.017_b1435","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1200\/JCO.22.01726","article-title":"Darolutamide maintenance in patients with metastatic castration-resistant prostate cancer with nonprogressive disease after taxane treatment (SAKK 08\/16)","volume":"41","author":"Gillessen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1440","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221149887","article-title":"Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review","volume":"15","author":"Mir","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1445","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.cger.2022.05.010","article-title":"Polypharmacy in oncology","volume":"38","author":"Cheng","year":"2022","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.eururo.2024.09.017_b1450","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1093\/oncolo\/oyac053","article-title":"Polypharmacy, potentially inappropriate medications, and drug-drug interactions in vulnerable older adults with advanced cancer initiating cancer treatment","volume":"27","author":"Ramsdale","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2024.09.017_b1455","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s10557-023-07453-0","article-title":"Pharmacokinetic interactions between abiraterone, apalutamide, darolutamide or enzalutamide and antithrombotic drugs: prediction of clinical events and review of pharmacological information","volume":"38","author":"Boujonnier","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.eururo.2024.09.017_b1460","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2017.03.001","article-title":"The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate\/prednisone and enzalutamide","volume":"55","author":"Del Re","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eururo.2024.09.017_b1465","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00280-017-3291-z","article-title":"Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France","volume":"79","author":"Bonnet","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.eururo.2024.09.017_b1470","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamaoncol.2022.1641","article-title":"Enzalutamide monotherapy vs active surveillance in patients with low-risk or intermediate-risk localized prostate cancer: the ENACT randomized clinical trial","volume":"8","author":"Shore","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1475","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.eururo.2015.01.027","article-title":"Long-term efficacy and safety of enzalutamide monotherapy in hormone-na\u00efve prostate cancer: 1- and 2-year open-label follow-up results","volume":"68","author":"Tombal","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.09.017_b1480","doi-asserted-by":"crossref","unstructured":"Tombal BF, Gomez-Veiga F, Gomez-Ferrer A, et al. A phase 2 randomized open-label study of oral darolutamide monotherapy versus androgen deprivation therapy in men with hormone-sensitive prostate cancer (EORTC-GUCG 1532). Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2024.01.009.","DOI":"10.1016\/j.euo.2024.01.009"},{"key":"10.1016\/j.eururo.2024.09.017_b1485","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5454727","article-title":"Randomized, open-label phase 2 study of apalutamide plus androgen deprivation therapy versus apalutamide monotherapy versus androgen deprivation monotherapy in patients with biochemically recurrent prostate cancer","volume":"2022","author":"Aggarwal","year":"2022","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.eururo.2024.09.017_b1490","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2021.08.032","article-title":"A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)","volume":"158","author":"Maluf","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2024.09.017_b1495","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00066-020-01598-9","article-title":"Treatment strategies to prevent and reduce gynecomastia and\/or breast pain caused by antiandrogen therapy for prostate cancer: statement from the DEGRO Working Group Prostate Cancer","volume":"196","author":"Ghadjar","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.eururo.2024.09.017_b1500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136094","article-title":"Gynecomastia in patients with prostate cancer: a systematic review","volume":"10","author":"Fagerlund","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2024.09.017_b1505","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.1016\/j.ijrobp.2012.01.036","article-title":"Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: tamoxifen or radiotherapy?","volume":"83","author":"Viani","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.09.017_b1510","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","article-title":"Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients","volume":"116","author":"Boyle","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2024.09.017_b1515","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/andr.12197","article-title":"Tamoxifen in men: a review of adverse events","volume":"4","author":"Wibowo","year":"2016","journal-title":"Andrology"},{"key":"10.1016\/j.eururo.2024.09.017_b1520","article-title":"Distribution and effects of estrogen receptors in prostate cancer: associated molecular mechanisms","volume":"12","author":"Ram\u00edrez-de-Arellano","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eururo.2024.09.017_b1525","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/biomedicines11030826","article-title":"The role of ER\u03b1 and ER\u03b2 in castration-resistant prostate cancer and current therapeutic approaches","volume":"11","author":"Jefferi","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.eururo.2024.09.017_b1530","first-page":"1286","article-title":"Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on muscle and bone health","volume":"25","author":"Bargiota","year":"2020","journal-title":"J BUON"},{"key":"10.1016\/j.eururo.2024.09.017_b1535","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1002\/cncr.24283","article-title":"Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer","volume":"115","author":"Taylor","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2024.09.017_b1540","doi-asserted-by":"crossref","unstructured":"Jones C, Gray S, Brown M, et al. Risk of fractures and falls in men with advanced or metastatic prostate cancer receiving androgen deprivation therapy and treated with novel androgen receptor signalling inhibitors: a systematic review and meta-analysis of randomised controlled trials. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2024.01.016.","DOI":"10.1016\/j.euo.2024.01.016"},{"key":"10.1016\/j.eururo.2024.09.017_b1545","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.eururo.2024.09.017_b1550","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.2024.42.4_suppl.330","article-title":"Pattern of testosterone recovery after androgen deprivation therapy","volume":"42","author":"Tam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.09.017_b1555","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1200\/JCO.2023.41.6_suppl.300","article-title":"Testosterone recovery in patients with prostate cancer treated with radiotherapy and different ADT duration: long-term data from two randomized trials","volume":"41","author":"Nabid","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1560","article-title":"Persistent testosterone suppression after cessation of androgen deprivation therapy for prostate cancer","volume":"14","author":"Delgado","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.eururo.2024.09.017_b1565","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","volume":"27","author":"Aubry-Rozier","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eururo.2024.09.017_b1570","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eururo.2024.09.017_b1575","doi-asserted-by":"crossref","first-page":"S581","DOI":"10.1097\/RHU.0000000000000979","article-title":"Spontaneous vertebral fractures in males with osteoporosis after denosumab discontinuation: a report of two cases","volume":"27","author":"Anagnostis","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.eururo.2024.09.017_b1580","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2022.100423","article-title":"Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: a real-world machine learning approach","volume":"34","author":"Jacobson","year":"2022","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1585","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.4335","article-title":"Fractures after denosumab discontinuation: a retrospective study of 797 cases","volume":"36","author":"Burckhardt","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eururo.2024.09.017_b1590","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","article-title":"Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study","volume":"34","author":"Tutaworn","year":"2023","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eururo.2024.09.017_b1595","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/oncolo\/oyac213","article-title":"Bone health and denosumab discontinuation in oncology populations","volume":"27","author":"Cheung","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2024.09.017_b1600","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2024.09.017_b1605","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2024.09.017_b1610","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.09.017_b1615","article-title":"Interventions for managing medication-related osteonecrosis of the jaw","volume":"2017","author":"Beth-Tasdogan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"15 Suppl","key":"10.1016\/j.eururo.2024.09.017_b1620","article-title":"Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: a noninferiority phase III trial (SAKK 96\/12, REDUSE)","volume":"32","author":"Templeton","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1625","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2020.08.019","article-title":"A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer","volume":"142","author":"Clemons","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2024.09.017_b1630","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2021.100388","article-title":"Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer","volume":"30","author":"Clemons","year":"2021","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1635","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2024.09.017_b1640","first-page":"870","article-title":"Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough?","volume":"73","author":"Turco","year":"2021","journal-title":"Minerva Urol Nephrol"},{"key":"10.1016\/j.eururo.2024.09.017_b1645","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/jbmr.1771","article-title":"Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy","volume":"28","author":"Greenspan","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2024.09.017_b1650","doi-asserted-by":"crossref","first-page":"S956","DOI":"10.1016\/j.annonc.2023.09.2718","article-title":"1768MO Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic hormone sensitive prostate cancer: analysis of routinely collected healthcare data from the STAMPEDE docetaxel and zoledronic acid comparisons","volume":"34","author":"Jones","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1655","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/annonc\/mdz136","article-title":"Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group","volume":"30","author":"Mandelker","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1660","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.19452","article-title":"Yield and utility of germline testing following tumor sequencing in patients with cancer","volume":"3","author":"Lincoln","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2024.09.017_b1665","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41525-023-00374-9","article-title":"Clinically significant germline pathogenic variants are missed by tumor genomic sequencing","volume":"8","author":"Stout","year":"2023","journal-title":"NPJ Genom Med"},{"key":"10.1016\/j.eururo.2024.09.017_b1670","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100526","article-title":"Discrepancies between tumor genomic profiling and germline genetic testing","volume":"7","author":"Pauley","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.eururo.2024.09.017_b1675","article-title":"Addition of germline testing to tumor-only sequencing improves detection of pathogenic germline variants in men with advanced prostate cancer","volume":"6","author":"Berchuck","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.eururo.2024.09.017_b1680","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824026101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824026101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T03:46:08Z","timestamp":1740368768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824026101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":336,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0302283824026101"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.09.017","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}